US20110212523A1 - Differentiation-inducing culture medium additive and use thereof - Google Patents

Differentiation-inducing culture medium additive and use thereof Download PDF

Info

Publication number
US20110212523A1
US20110212523A1 US13/127,774 US200913127774A US2011212523A1 US 20110212523 A1 US20110212523 A1 US 20110212523A1 US 200913127774 A US200913127774 A US 200913127774A US 2011212523 A1 US2011212523 A1 US 2011212523A1
Authority
US
United States
Prior art keywords
culture medium
differentiation
cell
serum
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/127,774
Other languages
English (en)
Inventor
Yukio Kato
Jin Chang Shao
Koichiro Tsuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hiroshima University NUC
Two Cells Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to HIROSHIMA UNIVERSITY, TWO CELLS CO., LTD. reassignment HIROSHIMA UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHAO, JIN CHANG, TSUJI, KOICHIRO, KATO, YUKIO
Publication of US20110212523A1 publication Critical patent/US20110212523A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Definitions

  • the present invention relates to a differentiation-inducing culture medium additive and a use thereof. More specifically, the present invention relates to a differentiation-inducing culture medium additive for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition, and to a use of the differentiation-inducing culture medium additive.
  • a stem cell is a cell having a self-reproducing potential and a differentiation potential.
  • an embryonic stem cell an ES cell
  • an induced pluripotent stem cell an iPS cell
  • a somatic stem cell are known as stem cells.
  • the somatic stem cell include: a hematopoietic stem cell, a neural stem cell, and a mesenchymal stem cell.
  • Each of the ES cell and the iPS cell has a pluriopotency to differentiate into any tissue.
  • the hematopoietic stem cell has a potential to differentiate into a blood cell.
  • the neural stem cell has a potential to differentiate into a nerve cell.
  • the mesenchymal stem cell is present in tissues of bone marrow or the like, and is known as a stem cell having a pluriopotency to differentiate into an adipose cell, a bone cell, a chondrocyte, or the like.
  • the mesenchymal stem cell is currently used as a cell for transplantation in a regenerative medicine field.
  • the mesenchymal stem cell is adapted to various diseases such as a bone defect, a cartilage defect, a periodontal disease, a myocardial infarction, a refractory dermatosis, osteoporosis, osteoarthrosis, a spinal cord injury, hematopoietic support, and antirejection in organ transplantation. It is expected that in the future, the mesenchymal stem cell will be adapted to more and more diseases (e.g., a cerebral infarction, arteriosclerosis obliterans, a kidney disorder, etc.).
  • diseases e.g., a cerebral infarction, arteriosclerosis obliterans, a kidney disorder, etc.
  • a culture medium to which an animal serum (generally 10 to 15% fetal bovine serum) is added is extensively used as a culture medium for inducing differentiation of the stem cells into various functional cells.
  • an animal serum generally 10 to 15% fetal bovine serum
  • Such a serum is used as a nutrient source for promoting in vitro cell growth and/or proliferation, or a supply source of a biologically active substance such as hormone.
  • a serum is very expensive, and components thereof differ for each lot because the serum is a natural product. This is highly likely to cause variation in promotion effect of cell differentiation.
  • cultured cells need to be purified so that serum-derived proteins or the like are removed from the cultured cells. This requires a complicated process.
  • cultured cells may be infected with an unknown pathogen (such as a virus or pathogenic prion) that is included in the serum.
  • the serum may contain a component inhibiting bone differentiation of the mesenchymal stem cell.
  • a method for carrying out bone differentiation by use of a reduced amount of serum.
  • a method for inducing differentiation of a mesenchymal stem cell into an osteoplastic cell by adding an epidermal growth factor (EGF) to a culture medium in which an amount of fetal bovine serum is reduced to 1% (see Non Patent Literature 1).
  • EGF epidermal growth factor
  • a technique is also known in which a composition containing a specific growth factor and a phospholipid is added to a basal medium, so as to induce a cell, which has been obtained by culturing a mesenchymal stem cell under a serum-free condition, to differentiate into an osteoblast cell or an adipose cell with the use of a serum-containing culture medium (see Patent Literature 1).
  • Non-Patent Literature 1 differentiation is induced in a serum-containing culture medium although a used amount of serum is reduced. This causes problems arising from serum such as variations in differentiation promotion effect, a complicated purification process, infection of cultured cells, and high cost of differentiation induction. Meanwhile, no finding has been made as for a method for inducing differentiation of a mesenchymal stem cell into an osteoblast cell under a serum-free condition.
  • the present invention was attained in view of the above problems, and an object of the present invention is to provide a differentiation-inducing culture medium additive for efficiently inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition at low cost, and a use of the differentiation-inducing culture medium additive.
  • a differentiation-inducing culture medium additive of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition at least contains: at least one growth factor selected from the group consisting of EGF, FGF, and PDGF; dexamethasone; and ⁇ -glycerophosphate.
  • the growth factor has a function of promoting a bone differentiation program of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast (these cells are hereinafter collectively referred to as “target cell”), and dexamethasone has a function of promoting survival and differentiation of cells, and ⁇ -glycerophosphate has a function of supplying phosphoric acid and promoting calcification. Accordingly, it is possible to efficiently induce bone differentiation of a target cell under a serum-free condition by adding the differentiation-inducing culture medium additive of the present invention to a basal medium.
  • the differentiation-inducing culture medium additive of the present invention preferably further contains at least one phospholipid.
  • the at least one phospholipid is preferably selected from the group consisting of phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl choline, and phosphatidylglycerol.
  • differentiation of a target cell can be induced due to the functions of the growth factor, dexamethasone, and ⁇ -glycerophosphate, and a signal transduction system for inducing bone differentiation of the target cell is activated due to the function of the at least one phospholipid.
  • This further promote the bone differentiation. Accordingly, it is possible to more efficiently induce bone differentiation of the target cell, thereby shortening a period of time required for the bone differentiation induction. As a result, it is possible to reduce cost for the bone differentiation induction.
  • the differentiation-inducing culture medium additive of the present invention preferably further contains an oxidation inhibitor.
  • the oxidation inhibitor is preferably DL- ⁇ -tocopherol acetate (vitamin E).
  • the arrangement it is possible to prevent degradation of the phospholipid. Accordingly, it is possible to more efficiently differentiate the target cell into a bone.
  • the differentiation-inducing culture medium additive is preferably used in inducing bone differentiation of a mesenchymal stem cell which is used as the stem cell.
  • the growth factor has a function of promoting a bone differentiation program
  • dexamethasone has a function of inducing a bone morphogenetic protein (BMP)
  • BMP bone morphogenetic protein
  • ⁇ -glycerophosphate is converted into inorganic phosphoric acid by alkaline phosphatase so as to supply phosphoric acid, and has a function of promoting calcification. Accordingly, it is possible to efficiently induce differentiation of a mesenchymal stem cell into an osteoblast cell under a serum-free condition by adding the differentiation-inducing culture medium additive of the present invention to a basal medium. Consequently, uniform and stable differentiation promotion effect can be obtained.
  • the differentiation-inducing culture medium additive further contains at least one phospholipid
  • a signal transduction system for inducing bone differentiation of a mesenchymal stem cell is activated. This further promotes the bone differentiation. Accordingly, it is possible to more efficiently induce differentiation of the mesenchymal stem cell into an osteoblast cell, thereby shortening a period of time required for the bone differentiation induction. As a result, it is possible to reduce cost for the bone differentiation induction.
  • a culture medium of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition contains: components constituting the differentiation-inducing culture medium additive of the present invention; and a basal medium, and the culture medium contains no serum.
  • the culture medium is preferably used in inducing bone differentiation of a mesenchymal stem cell which is used as the stem cell.
  • a culture method of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition includes the step of: differentiating at least one type of cell selected from the group consisting of the stem cell, the dental pulp cell, the periodontal ligament cell, the placenta, the amnion, and the fibroblast in the culture medium.
  • the culture method is preferably used in inducing bone differentiation of a mesenchymal stem cell which is used as the stem cell.
  • a kit of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition includes: components constituting the differentiation-inducing culture medium additive of the present invention.
  • the kit is preferably used in inducing bone differentiation of a mesenchymal stem cell which is used as the stem cell.
  • the differentiation-inducing culture medium additive of the present invention at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF; dexamethasone; and ⁇ -glycerophosphate. This makes it possible to induce bone differentiation of a target cell under a serum-free condition. Further, in a case where the differentiation-inducing culture medium additive contains at least one phospholipid, it is possible to further promote bone differentiation of the target cell under a serum-free condition.
  • the kit makes it possible to easily perform bone differentiation of a target cell, which has been conventionally difficult under a serum-free condition.
  • a mesenchymal stem cell is used as the stem cell, it is possible to efficiently induce differentiation of the mesenchymal stem cell into an osteoblast cell. Further, use of the kit makes it possible to easily perform differentiation of a mesenchymal stem cell into an osteoblast cell, which has been conventionally difficult under a serum-free condition.
  • the culture method for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition further includes the step of: proliferating at least one type of cell selected from the group consisting of the stem cell, the dental pulp cell, the periodontal ligament cell, the placenta, the amnion, and the fibroblast in a serum-free culture medium containing at least three growth factors selected from the group consisting of FGF, PDGF, EGF, TGF- ⁇ , and HGF and at least one phospholipid before the step of differentiating at least one type of cell selected from the group consisting of the stem cell, the dental pulp cell, the periodontal ligament cell, the placenta, the amnion, and the fibroblast in the culture medium of the present invention.
  • a differentiation potential of a target cell can be kept high in a case where the target cell is cultured in a serum-free culture medium (hereinafter referred to as “serum-free proliferation culture medium”) containing at least three growth factors selected from the group consisting of FGF, PDGF, EGF, TGF- ⁇ , and HGF and at least one phospholipids.
  • serum-free proliferation culture medium containing at least three growth factors selected from the group consisting of FGF, PDGF, EGF, TGF- ⁇ , and HGF and at least one phospholipids.
  • the target cell whose growth potential and pluriopotency are kept high can be efficiently bone-differentiated in the culture medium of the present invention.
  • This allows more efficient bone differentiation induction as compared with a case where bone differentiation of a target cell that has been cultured with the use of a general serum-containing proliferation culture medium is induced in the culture medium of the present invention.
  • it is possible to further shorten a period of time required for the bone differentiation induction.
  • An osteoblast cell of the present invention is produced by the culture method of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition.
  • the osteoblast cell of the present invention shows higher alizarin red stainability, which indicates calcification of an osteoblast cell, as compared with an osteoblast cell differentiated by a conventional bone differentiation-inducing method using a conventional bone differentiation-inducing culture medium. That is, the osteoblast cell of the present invention is an osteoblast cell in which more calcium is deposited, as compared with an osteoblast cell differentiated by a conventional bone differentiation-inducing method using a conventional bone differentiation-inducing culture medium.
  • the osteoblast cell of the present invention cultured in a serum-free culture medium can be used for bone defect and osteoporosis in orthopedics, dentistry etc., and is therefore useful for regeneration medicine.
  • a differentiation-inducing culture medium additive of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition, at least contains: at least one growth factor selected from the group consisting of EGF, FGF, and PDGF; dexamethasone; and ⁇ -glycerophosphate.
  • the differentiation-inducing culture medium additive of the present invention to a basal medium, it is possible to produce an effect that bone differentiation of a target cell can be efficiently induced under a serum-free condition and an effect that use of serum, which may include a pathogen and may cause variation in differentiation, can be avoided. Further, recombinant human insulin, transferrin, selenate, and ascorbic acid, which have been conventionally considered as being essential for bone differentiation induction, need not necessarily to be added. This makes it possible to provide a differentiation-inducing culture medium additive at lower cost.
  • FIG. 1 shows an observation result of how differentiation of mesenchymal stem cells into osteoblast cells was induced in a case where a bone differentiation-inducing culture medium containing 10% FBS was used and in a case where a serum-free bone differentiation-inducing culture medium: B was used.
  • FIG. 2 shows a result of study on how a growth factor influenced induction of differentiation of mesenchymal stem cells into osteoblast cells.
  • FIG. 3 shows a result of study on how EGF influenced induction of differentiation of mesenchymal stem cells into osteoblast cells in a case where a bone differentiation-inducing culture medium containing 10% FBS was used.
  • FIG. 4 shows a result of induction of differentiation of mesenchymal stem cells into osteoblast cells.
  • Differentiation-inducing culture medium additive for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition
  • a differentiation-inducing culture medium additive of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition (hereinafter simply referred to as “differentiation-inducing culture medium additive of the present invention”) at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF, dexamethasone, and ⁇ -glycerophosphate.
  • the “stem cell” used herein may be human-derived or animal-derived.
  • the “stem cell” is not limited to a specific one, provided that it can differentiate into an osteoblast cell.
  • Examples of the “stem cell” include an embryonic stem cell (an ES cell), an induced pluripotent stem cell (an iPS cell), and a somatic stem cell such as a mesenchymal stem cell.
  • the stem cell may be used in combination with a feeder cell or solely.
  • the somatic stem cell may be a primary somatic stem cell taken from a tissue or an established somatic stem cell.
  • the somatic stem cell may be a somatic stem cell obtained by differentiating the ES cell, iPS cell or the like.
  • the somatic stem cell may be, for example, a somatic stem cell that has not been differentiated completely or an undifferentiated somatic stem cell.
  • the stem cell to be differentiated may be a cell that has become confluent or a cell that has not become confluent yet.
  • the stem cell in a case where the mesenchymal stem cell is used as the stem cell, the stem cell can be, for example, bone marrow-derived, adipose-derived, periosteum-derived, synovium-derived, umbilical cord blood-derived, placenta-derived or finger-derived mesenchymal stem cell.
  • the mesenchymal stem cell in a case where the mesenchymal stem cell is differentiated into an osteoblast cell, the mesenchymal stem cell may be a mesenchymal stem cell that has not been differentiated into an osteoblast cell completely or an undifferentiated mesenchymal stem cell.
  • the mesenchymal stem cell to be differentiated may be a cell that has become confluent or a cell that has not become confluent yet.
  • Each of the dental pulp cell, periodontal ligament cell, placenta, amnion, and fibroblast may be human-derived or animal derived. Further, each of the dental pulp cell, periodontal ligament cell, placenta, amnion, and fibroblast may be used in combination with a feeder cell or solely. Further, each of the dental pulp cell, periodontal ligament cell, placenta, amnion, and fibroblast may be a primary cell taken from a tissue or an established cell.
  • the stem cell, dental pulp cell, periodontal ligament cell, placenta, amnion, and fibroblast may be used solely or in combination.
  • Dexamethasone and ⁇ -glycerophosphate are added to a basal medium in combination with the growth factor. This makes it possible to efficiently induce bone differentiation of a target cell under a serum-free condition. Specifically, it is possible to efficiently achieve formation of extracellular matrix and calcification of the osteoblast cell.
  • dexamethasone is preferably used in a range of 10 ⁇ 6 M to 10 ⁇ 10 M, more preferably in a range of 10 ⁇ 7 M to 10 ⁇ 9 M, which are final concentration in a culture medium to which the differentiation-inducing culture medium additive is added
  • ⁇ -glycerophosphate is preferably used in a range of 1 mM to 100 mM, more preferably in a range of 1 mM to 30 mM, which are final concentration in a culture medium to which the differentiation-inducing culture medium additive is added.
  • the EGF is an abbreviation of an epidermal growth factor, and is intended to mean a growth factor selected from an EGF family.
  • the EGF family includes, for example, EGF, TGF- ⁇ (transforming growth factor- ⁇ ), amphiregulin, HB-EGF (heparin-binding EGF-like growth factor), epiregulin, and neuregulin. Since the EGF is most commonly used and most inexpensive in the EGF family, the EGF is preferable used.
  • the FGF is an abbreviation of a fibroblast growth factor, and is intended to mean a growth factor selected from an FGF family.
  • the FGF is preferably FGF-2 (bFGF), but may be a different one, selected from the FGF family, such as FGF-1.
  • the term “PDGF” used herein refers to a growth factor selected from a PDFG (platelet derived growth factor) family.
  • the PDGF is preferably PFGF-BB or PDGF-AB.
  • the EGF or the PDGF is preferably used, and the EGF is especially preferably used, but it is also possible that two or more growth factors are used in any combination.
  • a combination of the EGF and FGF is preferably used, since use of the combination of the EGF and FGF makes it possible to induce differentiation of various different mesenchymal stem cell lines into an osteoblast cell and to promote the differentiation, as compared to a case where the EGF or FGF is used solely. Even in a case where other stem cells are used, two or more growth factors are preferably used in any combination since differentiation can be thus promoted.
  • an EGF content, a PDGF content, and an FGF content in the differentiation-inducing culture medium additive of the present invention are not limited in particular, but the EGF is preferably used in concentration of 0.5 ng/ml to 200 ng/ml, and the PDGF is preferably used in concentration of 0.5 ng/ml to 100 ng/ml, each of which concentration is final concentration in a culture medium to which the differentiation-inducing culture medium additive is added.
  • the FGF is preferably used in concentration of 0.1 ng/ml to 10 ⁇ g/ml.
  • the FGF is preferably used in concentration of 0.1 ng/ml to 100 ng/ml.
  • each of the compounds and the growth factors may be a natural one or a synthetic one or may be produced by gene recombination etc., provided that it has activity as a growth factor.
  • the culture medium additive for use in serum-free culture of animal cells (Patent Literature 1) developed by the inventors of the present invention allows a stem cell to be proliferated at a speed equal to or faster than a case where a stem cell is cultured in a culture medium containing 10% serum while maintaining its properties (an osteogenic differentiation potential, an adipogenic differentiation potential etc. in the case of a mesenchymal stem cell).
  • this culture medium additive cannot induce bone differentiation of a target cell (e.g., differentiation into an osteoblast cell, an adipose cell or the like in the case where the stem cell is a mesenchymal stem cell) under a serum-free condition. Accordingly, a conventional method requires the differentiation to be performed in the presence of serum.
  • the inventors of the present invention studied a culture method which makes it possible to induce bone differentiation of a target cell even under a serum-free condition.
  • the inventors of the present invention found that it is possible to induce differentiation of a target cell into an osteoblast cell even under a serum-free condition by adding, to a basal medium, a differentiation-inducing culture medium additive that at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF, dexamethasone, and ⁇ -glycerophosphate, and found that it is possible to efficiently induce especially differentiation of a mesenchymal stem cell into an osteoblast cell.
  • the inventors of the present invention found that use of a culture medium to which the differentiation-inducing culture medium additive of the present invention is added makes it possible to more efficiently induce bone differentiation and therefore makes it possible to shorten a period of time required for the bone differentiation induction, as compared with a case where bone differentiation induction is performed in the presence of serum.
  • the differentiation-inducing culture medium additive of the present invention preferably further contains at least one phospholipid. Even in a case where a differentiation-inducing culture medium additive which contains no phospholipid is used, it is possible to induce bone differentiation of a target cell. However, in a case where at least one phospholipid is added to the differentiation-inducing culture medium additive, it is possible to further improve efficiency of bone differentiation induction of a target cell and to further shorten a period of time required for the bone differentiation induction. On this account, the differentiation-inducing culture medium additive of the present invention preferably further contains at least one phospholipid. Note that it was first discovered by the present invention that a phospholipid promotes bone differentiation induction of a target cell under a serum-free condition.
  • the phospholipid is not limited to a specific one.
  • the phospholipid include phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl choline, and phosphatidylglycerol.
  • the differentiation-inducing culture medium additive of the present invention may contain these phospholipids solely or in combination. In a case where these phospholipids are used in combination, it is preferable that phosphatidic acid and phosphatidyl choline be used. Each of these phospholipids may be animal-derived or plant-derived.
  • a phospholipid content in the differentiation-inducing culture medium additive is not limited in particular, but it is preferable that one or more of the phospholipids be contained in the differentiation-inducing culture medium additive so that a culture medium to which the differentiation-inducing culture medium additive has been added contains the phospholipid alone or the phospholipids in total in a final concentration of 0.1 ⁇ g/ml to 30 ⁇ g/ml, most preferably in a final concentration of 10 ⁇ g/ml. Further, in a case where two or more of the phospholipids are used in combination, the phospholipids are preferably added so that the phospholipids are equal in final concentration to each other.
  • the culture medium to which the differentiation-inducing culture medium additive is added contains the phospholipid alone or the phospholipids in total in a final concentration of more than 30 ⁇ g/ml, the phospholipid or the phospholipids may become toxic to the cell. Accordingly, such final concentration is not preferable.
  • the differentiation-inducing culture medium additive preferably contains an oxidation inhibitor.
  • the oxidation inhibitor can prevent deterioration of the phospholipid.
  • examples of the oxidation inhibitor include DL- ⁇ -tocopherol acetate (vitamin E), dibutylhydroxytoluene (BHT), butylated hydroxyanisole (BHA), and catechin.
  • DL- ⁇ -tocopherol acetate (vitamin E) is especially preferably used.
  • An oxidation inhibitor content in the differentiation-inducing culture medium additive is not limited in particular.
  • the oxidation inhibitor is preferably used in concentration of 0.1 ⁇ g/ml to 50 ⁇ g/ml, which is final concentration in a culture medium to which the differentiation-inducing culture medium additive is added.
  • the differentiation-inducing culture medium additive may further contain insulin, transferrin, and selenate. Note, however, that the differentiation-inducing culture medium additive of the present invention does not necessarily need to contain insulin, transferrin, and selenate. Even in a case where the differentiation-inducing culture medium additive does not contain insulin, transferrin, and selenate, it is possible to sufficiently induce bone differentiation of a target cell. Since the differentiation-inducing culture medium additive of the present invention does not need to contain insulin, transferrin, and selenate that have been conventionally considered as being essential for bone differentiation induction of a stem cell, it is possible to induce bone differentiation at lower cost.
  • the insulin may be an insulin-like growth factor, and may be the one derived from a natural cell or the genetically modified one.
  • An insulin content, a transferring content, and a selenate content in the differentiation-inducing culture medium additive are not limited in particular, but the insulin is preferably used in concentration of 0.5 ⁇ g/ml to 50 ⁇ g/ml, and the transferrin is preferably used in concentration of 0.5 ⁇ g/ml to 50 ⁇ g/ml, each of which concentration is final concentration in a culture medium to which the differentiation-inducing culture medium additive is added.
  • the selenate is preferably used in concentration of 0.1 ng/ml to 50 ng/ml, more preferably in concentration of 0.5 ng/ml to 50 ng/ml.
  • the insulin, transferrin, and selenate may be commercially available ITS supplements.
  • the insulin, transferrin, and selenate may be appropriately mixed or separately added to the differentiation-inducing culture medium additive.
  • the differentiation-inducing culture medium additive of the present invention may contain components other than the above-mentioned components as long as the effect of the present invention of inducing bone differentiation of a target cell under a serum-free condition is not ruined.
  • the differentiation-inducing culture medium additive of the present invention may contain other glucocorticoid such as cortisol, corticosterone, cortisone, and prednisolone. These components are preferably contained in concentration of 10 ⁇ 10 M to 10 ⁇ 6 M, more preferably in concentration of 10 ⁇ 9 M to 10 ⁇ 7 M, each of which concentration is final concentration in a culture medium to which the differentiation-inducing culture medium additive is added.
  • a method for preparing the differentiation-inducing culture medium additive of the present invention is not limited to a specific one, and can be a conventionally known method.
  • the differentiation-inducing culture medium additive of the present invention can be prepared by appropriately mixing the above-mentioned components (at least one growth factor selected from the group consisting of EGF, FGF, and PDGF, dexamethasone, ⁇ -glycerophosphate etc.).
  • An additive component such as excipient, binder, preservative, stabilizer, emulsifier, osmotic pressure controlling agent, or base agent may be added to the differentiation-inducing culture medium additive of the present invention according to need.
  • the differentiation-inducing culture medium additive of the present invention can be formed into a medical preparation with the use of the additive component by a normal medical preparation formation method, and can be used as solid or liquid form such as tablet, power, granule, water-soluble powder, emulsion, oily agent, or suspension.
  • the differentiation-inducing culture medium additive is preferably used to induce differentiation of a mesenchymal stem cell into an osteoblast cell.
  • the growth factor contained in the differentiation-inducing culture medium additive of the present invention has a function of promoting a bone differentiation program, and dexamethasone has a function of inducing a bone morphogenetic protein (BMP), and ⁇ -glycerophosphate has a function of supplying phosphoric acid and promoting calcification of an osteoblast cell. Accordingly, it is possible to efficiently induce bone differentiation of an osteoblast cell. In a case where the phospholipid is further added, it is possible to further promote the bone differentiation of the osteoblast cell. Accordingly, the differentiation-inducing culture medium additive of the present invention is also effective at promoting bone differentiation of an osteoblast cell.
  • a culture medium of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition contains the components constituting the differentiation-inducing culture medium additive of the present invention and a basal medium, and contains no serum.
  • the components refer to the components described in the Section [1.].
  • the culture medium of the present invention at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF, dexamethasone, and ⁇ -glycerophosphate.
  • the culture medium of the present invention preferably further contains at least one phospholipid as one of the components since phospholipid can promote differentiation into an osteoblast cell under a serum-free condition.
  • the culture medium contains the components constituting the differentiation-inducing culture medium additive of the present invention and a basal medium
  • the components may be added in the form of the differentiation-inducing culture medium additive described in the Section [1.] or the components described in the Section [1.] may be separately added to the basal medium.
  • the basal medium refers to a culture medium for animal cells, and can be a conventionally known culture medium for animal cells.
  • the basal medium include a Ham's F12 medium, a ⁇ -MEM medium, a DMEM medium, an RPMI-1640 medium, and a MCDB201 medium. These basal media may be used solely or in combination.
  • the basal medium constituting the culture medium of the present invention is preferably a culture medium obtained by mixing the ⁇ -MEM medium and the MCDB201 medium at a ratio of 1:1.
  • the culture medium of the present invention can be obtained by mixing the components constituting the differentiation-inducing culture medium additive of the present invention and the basal medium.
  • the culture medium of the present invention can be prepared by adding, to the basal medium, the components described in the Section [1.] that have the final concentration described in the Section [1.]. The culture medium thus prepared is appropriately sterilized before use.
  • the culture medium allows differentiation of a target cell to be induced under a serum-free condition, but the culture medium is more preferably used to induce differentiation of a mesenchymal stem cell into an osteoblast cell.
  • the culture medium of the present invention contains the components constituting the differentiation-inducing culture medium additive of the present invention.
  • the growth factor contained in the differentiation-inducing culture medium additive has a function of promoting a bone differentiation program, and dexamethasone has a function of inducing a bone morphogenetic protein (BMP), and ⁇ -glycerophosphate has a function of supplying phosphoric acid and promoting calcification of an osteoblast cell. Accordingly, it is possible to efficiently induce bone differentiation of an osteoblast cell. In a case where the phospholipid is further added, it is possible to further promote the bone differentiation of the osteoblast cell. Accordingly, the culture medium of the present invention is also effective at promoting bone differentiation of an osteoblast cell.
  • a culture method of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition includes the step of performing differentiation-culture of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast in the culture medium of the present invention.
  • a culture condition is not limited in particular, provided that a target cell can be differentiated into an osteoblast cell.
  • a mesenchymal stem cell that has been cultured in a DMEM medium containing 10% FBS so as to reach a confluent state is cultured in the culture medium of the present invention in the presence of 5% CO 2 at 37° C. for 7 or more days as described in the later-described Example.
  • the mesenchymal stem cell can be differentiated into an osteoblast cell.
  • the culture condition is not limited to this.
  • the culture method of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition preferably includes the step of performing proliferation-culture of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast in a serum-free culture medium that contains at least three growth factors selected from the group consisting of FGF, PDGF, EGF, TGF- ⁇ , and HGF, and at least one phospholipid, before the step of performing differentiation-culture of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast in the culture medium of the present invention.
  • bone differentiation induction of a target cell that has been cultured with the use of the serum-free proliferation culture medium is performed in the culture medium of the present invention, it is possible to more efficiently induce bone differentiation, as compared to a case where bone differentiation induction of a target cell that has been cultured with the use of a general serum-containing proliferation culture medium (e.g., DMEM medium containing 10% FBS) is performed in the culture medium of the present invention. As a result, it is possible to further shorten a period of time required for the bone differentiation induction.
  • a general serum-containing proliferation culture medium e.g., DMEM medium containing 10% FBS
  • the serum-free proliferation culture medium contains at least three growth factors selected from the group consisting of FGF, PDGF, EGF, TGF- ⁇ , and HGF, and at least one phospholipid, and contains no serum.
  • the FGF, PDGF, EGF, and the phospholipid contained in the serum-free proliferation culture medium are as described in the Section [1.], and therefore are not explained repeatedly.
  • the TGF- ⁇ is an abbreviation of a transforming growth factor- ⁇ , and is intended to mean a growth factor selected from a TGF- ⁇ family.
  • the TGF- ⁇ is preferably TGF- ⁇ 3 , but may be a different one selected from the TGF- ⁇ family.
  • the HGF is an abbreviation of a hepatocyte growth factor.
  • a growth factor content in the serum-free proliferation culture medium is not limited in particular, but the PDGF is preferably used in concentration of 0.5 ng/ml to 100 ng/ml, the TGF- ⁇ is preferably used in concentration of 0.5 ng/ml to 100 ng/ml, the EGF is preferably used in concentration of 0.5 ng/ml to 200 ng/ml, and the HGF is preferably used in concentration of 0.1 ng/ml to 50 ng/ml, each of which concentration is final concentration in the serum-free proliferation culture medium.
  • the FGF is preferably used in concentration of 0.1 ng/ml to 10 ⁇ g/ml.
  • the FGF is preferably used in concentration of 0.1 ng/ml to 100 ng/ml.
  • a phospholipid content in the differentiation-inducing culture medium additive is not limited in particular, but it is preferable that one or more of the phospholipids be contained in the differentiation-inducing culture medium additive so that a culture medium to which the differentiation-inducing culture medium additive has been added contains the phospholipid alone or the phospholipids in total in a final concentration of 0.1 ⁇ g/ml to 30 ⁇ g/ml, most preferably in a final concentration of 10 ⁇ g/ml. Further, in a case where two or more of the phospholipids are used in combination, the phospholipids are preferably added so that the phospholipids are equal in final concentration to each other.
  • the culture medium to which the differentiation-inducing culture medium additive is added contains the phospholipid alone or the phospholipids in total in a final concentration of more than 30 ⁇ g/ml, the phospholipid or the phospholipids may become toxic to the cell. Accordingly, such final concentration is not preferable.
  • the serum-free proliferation culture medium may contain the phospholipids solely or in combination.
  • the serum-free proliferation culture medium contains a combination of phosphatidic acid and phosphatidyl choline.
  • the serum-free proliferation culture medium preferably further contains at least one fatty acid.
  • the fatty acid contained in the serum-free proliferation culture medium include linoleic acid, linolenic acid, arachidonic acid, myristic acid, oleic acid, palmitoyl acid, palmitic acid, and stearic acid.
  • the serum-free proliferation culture medium may contain these fatty acids solely or in combination.
  • the serum-free proliferation culture medium may further contain cholesterol in addition to the above fatty acid.
  • a fatty acid content in the serum-free proliferation culture medium is not limited in particular.
  • lipid concentrate (11905-031, produced by Gibco)
  • an undiluted solution of the lipid concentrate that is not less than 1/1000 to not more than 1/10 of the serum-free proliferation culture medium by volume is added.
  • the serum-free proliferation culture medium may further contain at least two factors selected from the group consisting of a connective tissue growth factor (CTGF), a vascular endothelial growth factor (VEGF), and an ascorbic acid compound.
  • CTGF connective tissue growth factor
  • VEGF vascular endothelial growth factor
  • ascorbic acid compound an ascorbic acid compound
  • the EGF and the ascorbic acid compound contained in the serum-free proliferation culture medium are as described in the Section [1.], and therefore are not explained repeatedly.
  • the VEGF is intended to mean a growth factor selected from a VEGF family.
  • the VEGF is preferably VEGF-A, but may be a different one, selected from the VEGF family, such as VEGF-B, VEGF-C, VEGF-D, VEGF-D, VEGF-E, PlGF (placental growth factor)-1 or PlGF-2.
  • a CTGF content, a VEGF content, and an ascorbic acid compound content in the serum-free proliferation culture medium are not limited in particular, but the CTGF is preferably used in concentration of 0.1 ⁇ g/ml to 20 ⁇ g/ml, the VEGF is preferably used in concentration of 0.5 ng/ml to 100 ng/ml, and the ascorbic acid compound is preferably used in concentration of 0.5 ⁇ g/ml to 200 ⁇ g/ml, each of which concentration is final concentration in the serum-free proliferation culture medium.
  • commercially available VEGF v3388, produced by Sigma Aldrich, Inc.
  • CTGF (036-19471, produced by Wako Pure Chemical Industries, Ltd.
  • the serum-free proliferation culture medium preferably contains a phospholipid oxidation inhibitor.
  • the phospholipid oxidation inhibitor is as described in the Section [1.], and therefore is not explained repeatedly.
  • the serum-free proliferation culture medium contains DL- ⁇ -tocopherol acetate (vitamin E) as the phospholipid oxidation inhibitor.
  • a phospholipid oxidation inhibitor content in the serum-free proliferation culture medium is not limited in particular, but the phospholipid oxidation inhibitor is preferably used in concentration of 0.1 ⁇ g/ml to 50 ⁇ g/ml, which is final concentration in the serum-free proliferation culture medium.
  • the serum-free proliferation culture medium may further contain a surfactant.
  • the serum-free proliferation culture medium contains Pluronic F-68 or Tween-80 as the surfactant.
  • the serum-free proliferation culture medium may further contain insulin, transferrin, and selenate.
  • the serum-free proliferation culture medium may further contain dexamethasone or other glucocorticoid.
  • the insulin, transferrin, selenate, dexamethasone, and other glucocorticoid are as described in the Section [1.], and therefore are not explained repeatedly.
  • An insulin content, a transferrin content, and a selenate content in the serum-free proliferation culture medium are not limited in particular, but the insulin is preferably used in concentration of 0.5 ⁇ g/ml to 50 ⁇ g/ml, the transferrin is preferably used in concentration of 0.5 ⁇ g/ml to 50 ⁇ g/ml, and the selenate is preferably used in concentration of 0.1 ng/ml to 50 ng/ml, each of which concentration is final concentration in the serum-free proliferation culture medium.
  • An amount of the otherglucocorticoid is not limited in particular, but the other glucocorticoid is preferably used in concentration of 10 ⁇ 10 M to 10 ⁇ 6 M, which is final concentration in the serum-free proliferation culture medium.
  • a method for preparing the serum-free proliferation culture medium is not limited to a specific one, and can be a conventionally known method.
  • the serum-free proliferation culture medium can be prepared by appropriately mixing, into a basal medium, the above-mentioned components (at least three growth factors selected from the group consisting of FGF, PDGF, EGF, TGF- ⁇ , and HGF and at least one phospholipid etc.).
  • An exemplary embodiment of such a serum-free proliferation culture medium is serum-free STK2 medium used in the later-described Example.
  • a method for performing proliferation-culture of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast with the use of the serum-free proliferation culture medium is not limited to a specific one, provided that a target cell is allowed to proliferate while preserving a differentiation potential of the target cell.
  • a mesenchymal stem cell seeded at a density of 5000 cells/cm 2 is cultured at 37° C. in the presence of 5% CO 2 while changing a culture medium every two or three days as described in the later-described Example.
  • the mesenchymal stem cell is allowed to proliferate while preserving a differentiation potential of the mesenchymal stem cell.
  • the method is not limited to this.
  • a degree of differentiation of a target cell into an osteoblast cell after culture can be examined with the use of a conventionally known bone differentiation marker.
  • a degree of differentiation of a target cell can be examined by staining the target cell with alizarin red.
  • the culture method allows bone differentiation of a target cell to be induced under a serum-free condition, but in particular, the culture method is more preferably used to induce differentiation of a mesenchymal stem cell into an osteoblast cell.
  • the culture method of the present invention includes the step of culturing at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast in the culture medium of the present invention.
  • the growth factor contained in the culture medium has a function of promoting a bone differentiation program, and dexamethasone has a function of inducing a bone morphogenetic protein (BMP), and ⁇ -glycerophosphate has a function of supplying phosphoric acid and promoting calcification of an osteoblast cell. Accordingly, it is possible to efficiently induce bone differentiation of an osteoblast cell. In a case where the phospholipid is further added, it is possible to further promote the bone differentiation of the osteoblast cell. Accordingly, the culture method of the present invention is also effective at promoting bone differentiation of an osteoblast cell.
  • dexamethasone has a function of inducing a bone morphogenetic protein (BMP)
  • ⁇ -glycerophosphate has a function of supplying phosphoric acid and promoting calcification of an osteoblast cell. Accordingly, it is possible to efficiently induce bone differentiation of an osteoblast cell. In a case where the phospholipid is further added, it is possible to further promote the bone differentiation of the osteo
  • Kit for inducing differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition [4. Kit for inducing differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition]
  • kits of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition includes the components constituting the differentiation-inducing culture medium additive of the present invention.
  • the kit may further contain a basal medium.
  • the kit contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF, dexamethasone, and ⁇ -glycerophosphate.
  • the kit preferably further contains at least one phospholipid as one of the components since phospholipid can further promote differentiation.
  • the phospholipid is preferably selected from the group consisting of phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl choline, and phosphatidylglycerol.
  • the kit may contain insulin, transferrin, and selenate.
  • the kit is not limited to the above arrangement, and can include other reagents and instruments.
  • the kit may include a culture plate for culturing a target cell and a reagent (e.g., alizarin red) for evaluating a degree of differentiation into an osteoblast cell or may include a target cell to be cultured.
  • a reagent e.g., alizarin red
  • the kit of the present invention may be provided as a single container that includes, in an appropriate amount and/or form, (i) differentiation-inducing culture medium additive, (ii) the compounds and the growth factors, or (iii) the compounds, the growth factors, the phospholipid, the basal medium, and other reagents.
  • the kit of the present invention may be provided as a plurality of containers that include these components separately.
  • the kit of the present invention may include an instruction manual describing a procedure etc. for carrying out the method of the present invention.
  • the kit of the present invention allows bone differentiation of a target cell to be induced under a serum-free condition, but in particular, the kit is more preferably used to induce differentiation of a mesenchymal stem cell into an osteoblast cell.
  • the kit of the present invention includes the components constituting the differentiation-inducing culture medium additive of the present invention.
  • the growth factor contained in the differentiation-inducing culture medium additive has a function of promoting a bone differentiation program, and dexamethasone has a function of inducing a bone morphogenetic protein (BMP), and ⁇ -glycerophosphate has a function of supplying phosphoric acid and promoting calcification of an osteoblast cell. Accordingly, it is possible to efficiently induce bone differentiation of an osteoblast cell. In a case where the phospholipid is further added, it is possible to further promote the bone differentiation of the osteoblast cell. Accordingly, the kit of the present invention is effective at promoting bone differentiation of an osteoblast cell.
  • An osteoblast cell of the present invention is produced by the culture method of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition.
  • the culture method of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition is as described in the Section [3.], and therefore is not explained repeatedly.
  • the osteoblast cell of the present invention shows higher alizarin red stainability, which indicates calcification of an osteoblast cell, as compared with an osteoblast cell differentiated by a conventional bone differentiation-inducing method using a conventional bone differentiation-inducing culture medium, as described in the later-described Example. That is, the osteoblast cell of the present invention is an osteoblast cell in which more calcium is deposited, as compared with an osteoblast cell differentiated by a conventional bone differentiation-inducing method using a conventional bone differentiation-inducing culture medium.
  • the osteoblast cell of the present invention cultured in a serum-free culture medium can be used for bone defect and osteoporosis in orthopedics, dentistry etc., and is therefore useful for regeneration medicine.
  • Mesenchymal stem cells were used as stem cells in Examples of the present invention. All the mesenchymal stem cells were cultured in a CO 2 incubator in the presence of 5% CO 2 at 37° C.
  • a culture medium (a serum-free proliferation culture medium) used to proliferate and culture mesenchymal stem cells is referred to as an STK2 culture medium in the Examples of the present invention.
  • Table 1 shows a composition of the STK2 culture medium.
  • “Source” in Table 1 indicates from where substances described in Table 1 were obtained and their model numbers. “Effective concentration” indicates acceptable final concentrations in which the respective substances were contained in the STK2 culture medium.
  • An effective concentration of the lipid concentrate (CD) is described as “1/1000 to 1/10”. This means that an undiluted solution of lipid concentrate is added in a volume ratio of not less than 1/1000 and not more than 1/10 to the STK2 culture medium. Note that surfactants Pluronic F68 and Tween 80 are contained in the lipid concentrate.
  • a culture medium used to induce differentiation into osteoblast cells is referred to as an STK0 culture medium in the Examples of the present invention.
  • ⁇ -MEM produced by Sigma Aldrich, Inc.
  • Table 2 shows a composition of the STK0 culture medium.
  • “Source” in Table 2 indicates from where substances described in Table 2 were obtained and their model numbers. “Effective concentration” indicates acceptable final concentrations in which the respective substances were contained in the STK0 culture medium.
  • An effective concentration of the lipid concentrate (CD) is described as “1/1000 to 1/10”. This means that an undiluted solution of lipid concentrate is added in a volume ratio of not less than 1/1000 and not more than 1/10 to the STK0 culture medium.
  • surfactants Pluronic F68 and Tween 80 are contained in the lipid concentrate.
  • “Optimum Concentration” indicates suitable amounts in which the respective substances were contained in the STK0 culture medium.
  • evaluation of differentiation into osteoblast cells was carried out by staining differentiation-induced cells with alizarin red (produced by: Wako Pure Chemical Industries, Ltd., model number: 011-01192).
  • the differentiation-induced cells were stained with alizarin red in accordance with a method described in an instruction manual of alizarin red.
  • Low differentiation refers to differentiation at a stage where the differentiation-induced cells slightly stained with alizarin red can be visually observed. For example, a case where the differentiation-induced cells showed stainability as shown in a photograph of wells of “serum-free bone differentiation-inducing culture medium B+PDGF” in FIG. 1 was evaluated as “low” differentiation.
  • “Moderate” differentiation refers to differentiation at a stage where the differentiation-induced cells moderately stained with alizarin red can be visually observed. For example, a case where the differentiation-induced cells showed stainability as shown in a photograph of wells of “serum-free bone differentiation-inducing culture medium B+FGF” in FIG. 1 was evaluated as “moderate” differentiation.
  • “High” differentiation refers to differentiation at a stage where the differentiation-induced cells highly stained with alizarin red can be visually observed throughout a 24-well microplate. For example, a case where the differentiation-induced cells showed stainability as shown in a photograph of wells of “serum-free bone differentiation-inducing culture medium B+EGF” in FIG. 1 was evaluated as “high” differentiation.
  • a cell line A Three human ilium-marrow-derived mesenchymal stem cell lines (hereinafter referred to as a cell line A, a cell line B, and a cell line C) (purchased from Bio-Whittaker Inc. (Walkersville, Md.)) were used as mesenchymal stem cells.
  • the cell line A is a fifth subculture of human ilium-marrow-derived mesenchymal stem cells and each of the cell lines B and C is a fourth subculture of human ilium-marrow-derived mesenchymal stem cells.
  • a DMEM culture medium containing 10% FBS was used to culture the mesenchymal stem cells.
  • the mesenchymal stem cells were seeded on a 6-well microplate containing the DMEM culture medium at a density of 5000 cells/cm 2 . Culture media were replaced every two or three days during the cell culture.
  • FBS fetal bovine serum
  • the mesenchymal stem cells were washed two times with PBS before becoming confluent. Then, the mesenchymal stem cells were incubated for two minutes in PBS containing 0.05% trypsin and 0.2 mM EDTA, so that the mesenchymal stem cells were detached from the microplate. Then, the mesenchymal stem cells were re-suspended with a plant-derived trypsin inhibitor (Produced by Sigma Aldrich, Inc.: T6522) that contained no serum.
  • a plant-derived trypsin inhibitor Provided by Sigma Aldrich, Inc.: T6522
  • the 24-well microplate to which bottom surface the mesenchymal stem cells were attached was washed two times with the serum-free DMEM culture medium on the fourth day of the culture. Then, the mesenchymal stem cells were cultured in respective culture media shown in Table 3 for 3 days, 7 days, 14 days, or 21 days. An old culture medium was replaced with an identical new one every two or three days during differentiation induction. On the third or seventh day of the culture for differentiation in the respective culture media shown in Table 3, evaluation of differentiation into osteoblast cells was carried out by staining the mesenchymal stem cells with alizarin red.
  • Bone differentiation-inducing culture media shown in Table 3 and used in Example 1 are described here.
  • “10% FBS-DMEM” is the DMEM culture medium containing 10% FBS in Table 3.
  • the “10% FBS-DMEM” was used as a control culture medium.
  • “10% FBS-bone differentiation-inducing culture medium” was prepared by adding, to ⁇ -MEM, FBS in a final concentration of 10% by weight, dexamethasone in a final concentration of 100 nM, ⁇ -glycerophosphate in a final concentration of 10 mM, and L-ascorbic acid 2-phosphate sesquimagnesium salt in a final concentration of 50 ⁇ g/ml.
  • the “10% FBS-bone differentiation-inducing culture medium” is identical to a conventionally publicly-known bone differentiation-inducing culture medium used in Patent Literature 1.
  • “Serum-free bone differentiation-inducing culture medium: A” was prepared by adding, to the STK0 culture medium which is a serum-free culture medium, ⁇ -glycerophosphate in a final concentration of 10 mM.
  • “A-(FGF-2)” was prepared by removing FGF-2 from the serum-free bone differentiation-inducing culture medium: A. Note that in the present description, the removal of FGF-2 from the serum-free bone differentiation-inducing culture medium: A can be carried out by, for example, preparing the serum-free bone differentiation-inducing culture medium: A to which only FGF-2 is not added. Same hereinafter applies to “TGF- ⁇ 3 was removed from the serum-free bone differentiation-inducing culture medium: A” etc.
  • A-(TGF- ⁇ 3 ) was prepared by removing TGF- ⁇ 3 from the serum-free bone differentiation-inducing culture medium: A.
  • A-HGF was prepared by removing HGF from the serum-free bone differentiation-inducing culture medium: A.
  • A-EGF was prepared by removing EGF from the serum-free bone differentiation-inducing culture medium: A.
  • A-(PDGF-BB) was prepared by removing PDGF-BB from the serum-free bone differentiation-inducing culture medium: A.
  • “Serum-free bone differentiation-inducing culture medium: B” was prepared by removing FGF-2, TGF- ⁇ 3 , HGF, EGF, and PDGF-BB from the serum-free bone differentiation-inducing culture medium: A.
  • “B+EGF” was prepared by adding EGF in a final concentration of 20 ng/ml to the serum-free bone differentiation-inducing culture medium: B.
  • “B+(FGF-2)” was prepared by adding FGF-2 in a final concentration of 1 ng/ml to the serum-free bone differentiation-inducing culture medium: B.
  • B+(TGF- ⁇ 3 ) was prepared by adding TGF- ⁇ 3 in a final concentration of 10 ng/ml to the serum-free bone differentiation-inducing culture medium: B.
  • B+HGF was prepared by adding HGF in a final concentration of 5 ng/ml to the serum-free bone differentiation-inducing culture medium: B.
  • B+(PDGF-BB) was prepared by adding PDGF-BB in a final concentration of 10 ng/ml to the serum-free bone differentiation-inducing culture medium: B.
  • FIG. 1 shows an observation result of how differentiation of mesenchymal stem cells into osteoblast cells was induced in a case where the “10% FBS-bone differentiation-inducing culture medium”, i.e., a conventionally publicly-known bone differentiation-inducing culture medium containing 10% FBS was used and a case where the serum-free bone differentiation-inducing culture medium: B was used.
  • the observation result was obtained for three samples per culture medium. The three samples are the cell lines A, B, and C from the left.
  • FIG. 2 shows a result of study on how a growth factor influenced induction of differentiation of mesenchymal stem cells into osteoblast cells.
  • FIG. 3 shows a result of study on how EGF influenced induction of differentiation of mesenchymal stem cells into osteoblast cells in a case where a bone differentiation-inducing culture medium containing 10% FBS was used.
  • B Serum-free bone differentiation- Undifferentiated Undifferentiated inducing culture medium: B (A ⁇ EGF ⁇ (TGF- ⁇ 3 ) ⁇ HGF ⁇ (FGF-2) ⁇ (PDGF-BB)) 10. B + EGF Differentiated Differentiated (Moderately) (Highly) 11. B + (FGF-2) Undifferentiated Differentiated (Moderately) 12. B + (TGF- ⁇ 3 ) Undifferentiated Undifferentiated 13. B + HGF Undifferentiated Undifferentiated 14. B + (PDGF-BB) Undifferentiated Differentiated (Low)
  • the serum-free bone differentiation-inducing culture medium: B shown in FIG. 1 refers to the serum-free bone differentiation-inducing culture medium: B shown in Table 3.
  • the serum-free bone differentiation-inducing culture medium: B was prepared by removing EGF, TGF- ⁇ 3 , HGF, FGF-2, and PDGF-BB from a culture medium prepared by adding 10 mM of ⁇ -glycerophosphate to the STK0 culture medium.
  • “serum-free bone differentiation-inducing culture medium: B+EGF” in FIG. 1 was prepared by adding EGF in a final concentration of 20 ng/ml to the serum-free bone differentiation-inducing culture medium: B. Same applies to “serum-free bone differentiation-inducing culture medium: B+FGF” etc.
  • the culture medium prepared by adding EGF to the serum-free bone differentiation-inducing culture medium: B was used, moderate differentiation was observed on the third day of the culture, and differentiation induction was much more advanced on the seventh day of the culture than on the twenty-first day of the culture carried out by use of the bone differentiation-inducing culture medium containing 10% FBS (see FIG. 1 and Table 3).
  • the serum-free bone differentiation-inducing culture medium: B was prepared by removing EGF, TGF- ⁇ 3 , HGF, FGF-2, and PDGF-BB from the culture medium prepared by adding 10 mM of ⁇ -glycerophosphate to the STK0 culture medium.
  • the serum-free bone differentiation-inducing culture medium B was prepared by causing a basal medium (in which MCDB and ⁇ -MEM were mixed in a ratio of 1:1) to contain dexamethasone, L-ascorbic acid 2-phosphate sesquimagnesium salt, ⁇ -glycerophosphate, fatty acids (linoleic acid, linolenic acid, arachidonic acid, myristic acid, oleic acid, palmitoyl acid, palmitic acid, and stearic acid), and phospholipids (phosphatidic acid and phosphatidylcholine), cholesterol, an oxidation inhibitor DL- ⁇ -tocopherol acetate (vitamin E), surfactants Pluronic F-68 and Tween 80, etc.
  • a basal medium in which MCDB and ⁇ -MEM were mixed in a ratio of 1:1
  • dexamethasone L-ascorbic acid 2-phosphate sesquimagnesium salt
  • the culture medium prepared by adding FGF-2 to the serum-free bone differentiation-inducing culture medium: B was used, the mesenchymal stem cells were in the undifferentiated state on the third day of the culture. On the seventh day of the culture, moderate differentiation into osteoblast cells was observed and differentiation induction was much more advanced than on the twenty-first day of the culture carried out by use of the bone differentiation-inducing culture medium containing 10% FBS (see FIG. 1 and Table 3). Further, in a case where the culture medium prepared by adding PDGF-BB to the serum-free bone differentiation-inducing culture medium: B was used, the mesenchymal stem cells were in the undifferentiated state on the third day of the culture. However, on the seventh day of the culture, low differentiation was observed and was more noticeable than on the fourteenth day of the culture carried out by use of the bone differentiation-inducing culture medium containing 10% FBS.
  • “serum-free bone differentiation-inducing culture medium: B+EGF” refers to a culture medium prepared by adding EGF in a final concentration of 20 ng/ml to the serum-free bone differentiation-inducing culture medium: B.
  • “serum-free bone differentiation-inducing culture medium: A-(FGF-2)” refers to a culture medium prepared by removing FGF-2 from the serum-free bone differentiation-inducing culture medium: A.
  • a culture period in FIG. 2 is set to seven days.
  • a photograph of wells in a left column indicated as “control” shows an experimental plot in which no ⁇ -glycerophosphate is contained and a photograph of wells in a right column shows an experimental plot in which ⁇ -glycerophosphate is contained in a final concentration of 10 mM.
  • FIG. 3 shows that addition of EGF to the 10% FBS-bone differentiation-inducing culture medium promotes differentiation into osteoblast cells.
  • differentiation in an experimental plot (see FIG. 3 ) in which EGF was added to the 10% FBS-bone differentiation-inducing culture medium was less advanced even on the fourteenth day of the culture than that in an experimental plot (see FIG. 1 ) in which EGF was added to the serum-free bone differentiation-inducing culture medium: B.
  • a cell line F Five human ilium-marrow-derived mesenchymal stem cell lines (hereinafter referred to as a cell line F, a cell line G, a cell line H, a cell line I, and a cell line J) (purchased from Bio-Whittaker Inc. (Walkersville, Md.)) were used as mesenchymal stem cells.
  • each of the cell lines F, H, and I is a fifth subculture of human ilium-marrow-derived mesenchymal stem cells
  • each of the cell lines G and J is a fourth subculture of human ilium-marrow-derived mesenchymal stem cells.
  • a DMEM culture medium containing 10% FBS was used to proliferate and culture the mesenchymal stem cells.
  • the mesenchymal stem cells were seeded on a 6-well microplate containing the DMEM culture medium containing 10% FBS at a density of 5000 cells/cm 2 . Culture media were replaced every two or three days during the
  • the 24-well microplate to which the mesenchymal stem cells were attached was washed two times with a serum-free DMEM culture medium on the fourth day of the culture. Then, the mesenchymal stem cells were cultured in respective culture media shown in Table 4 for 7 days, 14 days, or 21 days. An old culture medium was replaced with an identical new one every two or three days during differentiation induction. On the seventh, fourteenth, or twenty-first day of the culture for differentiation in the respective culture media shown in Table 4, evaluation of differentiation of the mesenchymal stem cells into osteoblast cells was carried out by staining the mesenchymal stem cells with alizarin red.
  • “Serum-free bone differentiation-inducing culture medium: B” is identical to that used in Example 1.
  • “B+EGF”, “B+(FGF-2)”, “B+(TGF- ⁇ 3 )”, “B+HGF”, and “B+(PDGF-BB)” culture media are also identical to those used in Example 1.
  • “Serum-free bone differentiation-inducing culture medium: C” was prepared by adding FGF-2 and EGF in respective final concentrations of 1 ng/ml and 20 ng/ml to the serum-free bone differentiation-inducing culture medium: B.
  • “C-Dex” was prepared by removing dexamethasone from the serum-free bone differentiation-inducing culture medium: C.
  • C-VC was prepared by removing L-ascorbic acid 2-phosphate sesquimagnesium salt from the serum-free bone differentiation-inducing culture medium: C.
  • “C-( ⁇ -glycerophosphate)” was prepared by removing ⁇ -glycerophosphate from the serum-free bone differentiation-inducing culture medium: C.
  • C-PA-PC was prepared by removing phosphatidylcholine and phosphatidic acid salt from the serum-free bone differentiation-inducing culture medium: C.
  • C-CD was prepared by removing a lipid concentrate from the serum-free bone differentiation-inducing culture medium: C.
  • C—LiCl was prepared by removing LiCl from the serum-free bone differentiation-inducing culture medium: C.
  • C-ITS was prepared by removing insulin, transferrin, and selenate from the serum-free bone differentiation-inducing culture medium: C.
  • C-CD-LiCl was prepared by removing the lipid concentrate and LiCl from the serum-free bone differentiation-inducing culture medium: C.
  • C-CD-LiCl-VC+(PDGF-BB) was prepared by adding PDGF-BB in a final concentration of 10 ng/ml to a culture medium obtained by removing, from the serum-free bone differentiation-inducing culture medium: C, the lipid concentrate, LiCl, and L-ascorbic acid 2-phosphate sesquimagnesium salt.
  • Table 4 shows a result of bone differentiation which result was obtained on the seventh day after the beginning of differentiation induction.
  • Table 5 shows a result of bone differentiation which result was obtained on the fourteenth day after the beginning of differentiation induction.
  • Table 6 shows a result of bone differentiation which result was obtained on the twenty-first day after the beginning of differentiation induction.
  • Serum-free bone differentiation- Differentiated Differentiated Differentiated Differentiated Undifferentiated Undifferentiated inducing culture medium C (Low) (Low) (Low) (Serum-free bone differentiation-inducing culture medium: B + FGF + EGF) 10.
  • Serum-free bone differentiation- Differentiated Differentiated Differentiated Differentiated Differentiated inducing culture medium C (Highly) (Moderately) (Highly) (Moderately) (Serum-free bone differentiation-inducing culture medium: B + FGF + EGF) 10.
  • Serum-free bone differentiation- Differentiated Differentiated Differentiated Differentiated Differentiated inducing culture medium C (Highly) (Highly) (Highly) (Moderately) (Serum-free bone differentiation-inducing culture medium: B + FGF + EGF) 10.
  • the “serum-free bone differentiation-inducing culture medium: B”, i.e., the culture medium prepared by removing EGF, TGF- ⁇ 3 , HGF, FGF-2, and PDGF-BB from the culture medium prepared by adding 10 mM of ⁇ -glycerophosphate to the STK0 culture medium was used, no differentiation into osteoblast cells was observed even on the twenty-first day after the beginning of differentiation induction. This revealed that in order to carry out bone differentiation induction under a serum-free condition, it is essential to add some growth factor to a culture medium.
  • EGF and PDGF-BB are suitable to cause mesenchymal stem cells to differentiate into osteoblast cells with high efficiency and other growth factors such as TGF- ⁇ 3 and HGF are unsuitable to cause mesenchymal stem cells to differentiate into osteoblast cells.
  • the results obtained by carrying out differentiation induction by use of the culture media 9 through 18 in Tables 4 through 6 revealed that in order to induce differentiation into osteoblast cells, another factor in addition to the growth factor needs to be added to the serum-free bone differentiation-inducing culture medium: C.
  • C In a case where differentiation induction was carried out by use of the culture media 11 and 14 through 16, i.e., even in a case where any one of factors of L-ascorbic acid 2-phosphate sesquimagnesium salt, the lipid concentrate, ITS, and lithium chloride was not added to the serum-free bone differentiation-inducing culture medium: C, low differentiation into osteoblast cells was observed on the seventh day after the beginning of differentiation induction (see Table 4).
  • Example 2 also revealed that ITS and ascorbic acid, which have been considered to be essential factors for induction of differentiation into osteoblast cells, are not necessarily needed. Therefore, according to the present invention, it is possible to provide a bone differentiation-inducing culture medium additive at a lower price since ITS and ascorbic acid do not need to be added thereto.
  • C-CD the culture medium prepared by removing the lipid concentrate from the serum-free bone differentiation-inducing culture medium: C
  • differentiation into osteoblast cells was further promoted as compared to a case where the serum-free bone differentiation-inducing culture medium: C was used. This revealed that a fatty acid had an inhibitory influence on differentiation into osteoblast cells.
  • the “C-PA-PC” culture medium i.e., the culture medium prepared by removing the phospholipids (phosphatidylcholine and phosphatidic acid salt) from the serum-free bone differentiation-inducing culture medium: C was used, differentiation into osteoblast cells was carried out at lower efficiency as compared to the case where the serum-free bone differentiation-inducing culture medium: C was used. This revealed that, in a case where phospholipids were added to the serum-free bone differentiation-inducing culture medium, differentiation into osteoblast cells were further promoted.
  • FIGS. 1 through 3 and Tables 3 through 6 revealed that, in a case where a serum-free culture medium contained a suitable growth factor and a chemical compound, the mesenchymal stem sells were more highly induced to differentiate into osteoblast cells as compared to a case where the mesenchymal stem sells were cultured by use of a culture medium containing serum in high concentration.
  • the mesenchymal stem sells can be induced to differentiate into osteoblast cells under a serum-free condition in a case where a serum-free culture medium at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF, dexamethasone, and ⁇ -glycerophosphate.
  • the results of the Examples also revealed that, in a case where the serum-free culture medium further contains at least one phospholipid in addition to the at least one growth factor, dexamethasone, and ⁇ -glycerophosphate, differentiation into osteoblast cells is further promoted.
  • mesenchymal stem sells can be induced to differentiate into osteoblast cells under a serum-free condition.
  • at least one phospholipid is further added to the basal medium, differentiation into osteoblast cells can be induced with higher efficiency.
  • Table 7 shows an example of a suitable composition of a serum-free culture medium.
  • a serum-free culture medium having the composition shown in Table 7 is hereinafter referred to as an “STK3 culture medium”.
  • a cell line K Three human ilium-marrow-derived mesenchymal stem cell lines (hereinafter referred to as a cell line K, a cell line L, and a cell line M) (purchased from Bio-Whittaker Inc. (Walkersville, Md.)) were used as mesenchymal stem cells.
  • the cell line K is an eighth subculture of human ilium-marrow-derived mesenchymal stem cells
  • the cell line L is a seventh subculture of human ilium-marrow-derived mesenchymal stem cells
  • the cell line M is a tenth subculture of human ilium-marrow-derived mesenchymal stem cells.
  • the mesenchymal stem cells were seeded on a 6-well microplate containing a serum-free STK2 culture medium at a density of 5000 cells/cm 2 . Culture media were replaced every two or three days during the cell culture.
  • the mesenchymal stem cells were washed two times with PBS before becoming confluent. Then, the mesenchymal stem cells were incubated for two minutes in PBS containing 0.05% trypsin and 0.2 mM EDTA, so that the mesenchymal stem cells were detached from the microplate. Then, the mesenchymal stem cells were re-suspended with a plant-derived trypsin inhibitor (Produced by Sigma Aldrich, Inc.: T6522) that contained no serum.
  • a plant-derived trypsin inhibitor Provided by Sigma Aldrich, Inc.: T6522
  • the 24-well microplate to which bottom surface the mesenchymal stem cells in a confluent state were attached was washed two to three times with a serum-free DMEM culture medium. Differentiation-culture was carried out by use of a 10% FBS-bone differentiation-inducing culture medium or a serum-free bone differentiation-inducing culture medium (STK3 culture medium).
  • the “10% FBS-bone differentiation-inducing culture medium” was prepared by adding, to ⁇ -MEM, FBS in a final concentration of 10% by weight, dexamethasone in a final concentration of 100 nM, ⁇ -glycerophosphate in a final concentration of 10 mM, and L-ascorbic acid 2-phosphate sesquimagnesium salt in a final concentration of 50 ⁇ g/ml.
  • the “10% FBS-bone differentiation-inducing culture medium” is identical to a conventionally publicly-known bone differentiation-inducing culture medium used in Patent Literature 1. An old culture medium was replaced with an identical new one every two or three days during differentiation induction.
  • the mesenchymal stem cells were seeded on a 6-well microplate containing a DMEM culture medium containing 10% FBS at a density of 5000 cells/cm 2 . Culture media were replaced every two or three days during the cell culture.
  • the mesenchymal stem cells were washed two times with PBS before becoming confluent. Then, the mesenchymal stem cells were incubated for two minutes in PBS containing 0.05% trypsin and 0.2 mM EDTA, so that the mesenchymal stem cells were detached from the microplate. Then, the mesenchymal stem cells were re-suspended with a plant-derived trypsin inhibitor (Produced by Sigma Aldrich, Inc.: T6522) that contained no serum.
  • a plant-derived trypsin inhibitor Provided by Sigma Aldrich, Inc.: T6522
  • the mesenchymal stem cells were cultured at 37° C. in a CO 2 incubator with 5% CO 2 until becoming confluent.
  • the 24-well microplate to which bottom surface the mesenchymal stem cells in a confluent state were attached was washed two to three times with a serum-free DMEM culture medium.
  • Differentiation-culture was carried out by use of a 10% FBS-bone differentiation-inducing culture medium or a serum-free bone differentiation-inducing culture medium (STK3 culture medium).
  • An old culture medium was replaced with an identical new one every two or three days during differentiation induction.
  • evaluation of differentiation into osteoblast cells was carried out by staining the mesenchymal stem cells with alizarin red.
  • FIG. 4 and Tables 8 through 11 show results.
  • FIG. 4 shows a result of induction of differentiation of the mesenchymal stem cells into osteoblast cells.
  • Table 8 shows a result of bone differentiation which result was obtained on the fourth day after the beginning of differentiation induction.
  • Table 9 shows a result of bone differentiation which result was obtained on the seventh day after the beginning of differentiation induction.
  • Table 10 shows a result of bone differentiation which result was obtained on the fourteenth day after the beginning of differentiation induction.
  • Table 11 shows a result of bone differentiation which result was obtained on the twenty-first day after the beginning of differentiation induction.
  • the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium and differentiation-induced by use of the serum-free STK3 culture medium were already differentiating into osteoblast cells on the fourth day after the beginning of bone differentiation induction (see FIG. 4 and Table 8).
  • the mesenchymal stem cells proliferated and cultured by use of the STK2 culture medium and differentiation-induced by use of the (conventional) 10% FBS-bone differentiation-inducing culture medium were in an undifferentiated state.
  • the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the serum-free STK3 culture medium and (ii) the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the 10% FBS-bone differentiation-inducing culture medium were in the undifferentiated state.
  • each of (i) the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the serum-free STK3 culture medium and (ii) the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium and differentiation-induced by use of the serum-free STK3 culture medium were already differentiating into osteoblast cells on the seventh day after the beginning of bone differentiation induction (see FIG. 4 and Table 9).
  • the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium and differentiation-induced by use of the serum-free STK3 culture medium were slightly higher in degree of differentiation into osteoblast cells than the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the serum-free STK3 culture medium.
  • the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the 10% FBS-bone differentiation-inducing culture medium were lower in degree of differentiation into osteoblast cells than the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the serum-free STK3 culture medium.
  • the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium and differentiation-induced by use of the serum-free STK3 culture medium were higher in degree of differentiation into osteoblast cells than the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the serum-free STK3 culture medium.
  • Each of (i) the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the serum-free STK3 culture medium and (ii) the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium and differentiation-induced by use of the serum-free STK3 culture medium was high in degree of differentiation into osteoblast cells on the twenty-first day after the beginning of bone differentiation induction (see FIG. 4 and Table 11).
  • the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS and differentiation-induced by use of the 10% FBS-bone differentiation-inducing culture medium were lower in degree of differentiation into osteoblast cells than the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium and differentiation-induced by use of the 10% FBS-bone differentiation-inducing culture medium.
  • Example 3 revealed that in the case where the serum-free STK3 culture medium was used, the mesenchymal stem cells could be differentiated into osteoblast cells with higher efficiency and in a shorter period than in the case where the conventional 10% FBS-bone differentiation-inducing culture medium was used. This revealed that the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium maintained a higher potential for differentiating into osteoblast cells than the mesenchymal stem cells proliferated and cultured by use of the DMEM culture medium containing 10% FBS.
  • Example 3 show that the mesenchymal stem cells proliferated and cultured by use of the serum-free STK2 culture medium and differentiation-induced by use of the serum-free STK3 culture medium were already differentiating into osteoblast cells on the fourth day after the beginning of bone differentiation induction. It can be hypothesized that this is because use of the serum-free STK2 culture medium and the serum-free STK3 culture medium in combination synergistically promoted induction of differentiation of the mesenchymal stem cells into osteoblast cells.
  • a serum-free culture medium to which a differentiation-inducing culture medium additive of the present invention for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition is added allows higher degree of bone differentiation of the at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast than a conventional differentiation-inducing culture medium containing a serum. Therefore, the differentiation-inducing culture medium additive is suitably usable for regenerative medicine, for example.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US13/127,774 2008-11-11 2009-10-22 Differentiation-inducing culture medium additive and use thereof Abandoned US20110212523A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-289146 2008-11-11
JP2008289146 2008-11-11
PCT/JP2009/005573 WO2010055616A1 (ja) 2008-11-11 2009-10-22 分化誘導培地用添加剤およびその利用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/005573 A-371-Of-International WO2010055616A1 (ja) 2008-11-11 2009-10-22 分化誘導培地用添加剤およびその利用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/885,134 Division US10131877B2 (en) 2008-11-11 2015-10-16 Differentiation-inducing culture medium additive and use thereof

Publications (1)

Publication Number Publication Date
US20110212523A1 true US20110212523A1 (en) 2011-09-01

Family

ID=42169763

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/127,774 Abandoned US20110212523A1 (en) 2008-11-11 2009-10-22 Differentiation-inducing culture medium additive and use thereof
US14/885,134 Active US10131877B2 (en) 2008-11-11 2015-10-16 Differentiation-inducing culture medium additive and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/885,134 Active US10131877B2 (en) 2008-11-11 2015-10-16 Differentiation-inducing culture medium additive and use thereof

Country Status (6)

Country Link
US (2) US20110212523A1 (de)
EP (1) EP2351831B1 (de)
JP (1) JP5660572B2 (de)
KR (1) KR101712501B1 (de)
AU (1) AU2009315204B2 (de)
WO (1) WO2010055616A1 (de)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100172863A1 (en) * 2009-01-03 2010-07-08 Wasielewski Ray C Enhanced medical implant
EP2899266A1 (de) * 2014-01-24 2015-07-29 Fresenius Medical Care Deutschland GmbH Verbesserte Differenzierung mesenchymaler Stammzellen zu Osteoblasten
US20160024460A1 (en) * 2013-03-12 2016-01-28 Agency For Science, Technology And Research Method for culturing cells
US10328103B2 (en) 2009-01-03 2019-06-25 Ray C. Wasielewski Medical treatment composition comprising mammalian dental pulp stem cells
US10507266B2 (en) 2013-08-01 2019-12-17 Two Cells Co., Ltd. Cartilage-damage treatment agent and method for producing same
CN112175899A (zh) * 2019-07-04 2021-01-05 陕西佰傲干细胞再生医学有限公司 间充质干细胞成骨定向分化诱导液及其应用
CN112608891A (zh) * 2020-12-18 2021-04-06 云南中科灵长类生物医学重点实验室 一种间充质干细胞无血清培养基及其应用
US20220049224A1 (en) * 2019-10-30 2022-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Culture modifications of stem cells to enhance therapeutic recovery from tissue damage and ischemia-reperfusion injury and delayed organ function
CN114517178A (zh) * 2022-02-25 2022-05-20 北京三有利康细胞科技有限公司 Trolox在延缓间充质干细胞衰老中的应用
CN116590225A (zh) * 2023-05-12 2023-08-15 浙江大学 磷脂酰胆碱在制备促进猪FAPs细胞分化聚酯制剂中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6399734B2 (ja) * 2013-07-01 2018-10-03 国立研究開発法人理化学研究所 分化転換制御方法および基板
CN106890364A (zh) * 2015-12-17 2017-06-27 西安组织工程与再生医学研究所 一种工程化牙周组织的制备方法
CN107345216B (zh) * 2017-07-28 2020-11-06 暨南大学 一种脂肪干细胞培养基及其应用
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
WO2020032651A1 (ko) * 2018-08-09 2020-02-13 부산대학교 산학협력단 Lpar2 저해제를 포함하는 상아질-치수질환 또는 치주질환 예방 또는 치료용 약학적 조성물
WO2020100788A1 (ja) * 2018-11-14 2020-05-22 株式会社片岡製作所 インスリン産生細胞の製造方法、及び組成物
EP4100432A1 (de) * 2020-02-03 2022-12-14 Mosa Meat B.V. Serumfreies medium zur kultivierung einer rindervorläuferzelle
CN115044542B (zh) * 2022-06-30 2023-09-26 上海市东方医院（同济大学附属东方医院） Sj000291942在诱导间充质干细胞成骨分化方面的应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274445A2 (de) * 1987-01-09 1988-07-13 Medi-Cult A/S Serumfreie Kulturmittelzutat und ihre Verwendung
US20030143737A1 (en) * 1999-12-07 2003-07-31 Monash University Long-term cell-culture compositions and genetically modified animals derived therefrom
US6617159B1 (en) * 1998-11-09 2003-09-09 Consorzio Per La Gestione Del Centro Di Biotechnologie Avanzate Serum free medium for chondrocyte cells
US20030211604A1 (en) * 2002-01-25 2003-11-13 E. Brown Liesbeth Maria Serum-free media for chondrocytes and methods of use thereof
WO2004069172A2 (en) * 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
US20050032122A1 (en) * 2003-08-06 2005-02-10 Shiaw-Min Hwang Optimizing culture medium for CD34<+> hematopoietic cell expansion
US20050265980A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
US20060216821A1 (en) * 2004-02-26 2006-09-28 Reliance Life Sciences Pvt. Ltd. Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof
WO2007080919A1 (ja) * 2006-01-13 2007-07-19 Japan Science And Technology Agency 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用
US20090202654A1 (en) * 2005-12-14 2009-08-13 Organogenesis, Inc. Skin Care Compositions and Treatments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08308561A (ja) 1995-05-16 1996-11-26 Sumitomo Electric Ind Ltd 動物細胞培養用無血清培地
JPH09191874A (ja) 1996-01-22 1997-07-29 Kurabo Ind Ltd 正常ヒトメラニン細胞培養用無血清培地
US5834418A (en) 1996-03-20 1998-11-10 Theratechnologies, Inc. Process for the preparation of platelet growth factors extract
JP4740452B2 (ja) 1998-03-18 2011-08-03 オシリス セラピューティクス，インコーポレイテッド 移植で免疫応答の予防と処置のための間葉幹細胞を利用する方法、組成物およびその使用法
EP1325953A4 (de) 2000-09-12 2006-03-22 Yukio Kato Methode zur kultivierung von mesenchymalen stammzellen
GB2405642B (en) 2002-06-07 2007-03-28 Es Cell Int Pte Ltd Methods of regulating differentiation in stem cells
JP2007000077A (ja) * 2005-06-23 2007-01-11 Hitachi Medical Corp 付着性動物細胞の無血清培養方法及び付着性動物細胞の無血清培養用培地
WO2009114860A2 (en) 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274445A2 (de) * 1987-01-09 1988-07-13 Medi-Cult A/S Serumfreie Kulturmittelzutat und ihre Verwendung
US7109032B2 (en) * 1998-11-09 2006-09-19 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum-free medium for mesenchymal stem cells
US6617159B1 (en) * 1998-11-09 2003-09-09 Consorzio Per La Gestione Del Centro Di Biotechnologie Avanzate Serum free medium for chondrocyte cells
US20050090002A1 (en) * 1998-11-09 2005-04-28 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum free medium for chondrocyte-like cells
US20030143737A1 (en) * 1999-12-07 2003-07-31 Monash University Long-term cell-culture compositions and genetically modified animals derived therefrom
US20050132426A1 (en) * 1999-12-07 2005-06-16 Morrison John R. Long-term cell culture compositions and genetically modified animals derived therefrom
US20030211604A1 (en) * 2002-01-25 2003-11-13 E. Brown Liesbeth Maria Serum-free media for chondrocytes and methods of use thereof
US20070275463A1 (en) * 2002-01-25 2007-11-29 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US7169610B2 (en) * 2002-01-25 2007-01-30 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
WO2004069172A2 (en) * 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
US20050032122A1 (en) * 2003-08-06 2005-02-10 Shiaw-Min Hwang Optimizing culture medium for CD34<+> hematopoietic cell expansion
US20060216821A1 (en) * 2004-02-26 2006-09-28 Reliance Life Sciences Pvt. Ltd. Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof
US20050272152A1 (en) * 2004-05-14 2005-12-08 Becton, Dickinson And Company Stem cell populations and methods of use
US20050265980A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
US20090202654A1 (en) * 2005-12-14 2009-08-13 Organogenesis, Inc. Skin Care Compositions and Treatments
WO2007080919A1 (ja) * 2006-01-13 2007-07-19 Japan Science And Technology Agency 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用
US20100279412A1 (en) * 2006-01-13 2010-11-04 Japan Science And Technology Agency Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Broedel et al. The case for serum-free media. BioProcess International. 2003;56-58. *
GIBCO Invitrogen Cell Culture. StemPro Osteogenesis Differentiation Kit. 2008. *
Kotev-Emeth et al. Establishment of a rat long-term culture expressing the osteogenic phenotype: Dependence on dexamethasone and FGF-2. Connective Tissue Research. 2002;43:606-612. *
Pasco et al. Antioxidant vitamin supplements and markers of bone turnover in a community sample of nonsmoking women. Journal of Women's Health. 2006;15(3):295-300. *
Peter et al. Osteoblastic phenotype of rat marrow stromal cells cultured in the presence of dexamethasone, beta-glycerolphosphate, and L-ascorbic acid. Journal of Cellular Biochemistry. 1998;71:55-62. *
Sandstrom et al. Review: serum-free media for cultures of primitive and mature hematopoietic cells. Biotechnology and Bioengineering. 1994;43:706-733. *
Shioi et al. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:2003-2009. *
Singh et al. Parathyroid hormone stimulates phosphatidylethanolamine hydrolysis by phospholipase D in osteoblastic cells. Lipids. 2005;40(11):1135-1140. *
Valta et al. Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology. 2006;147(5):2171-2182. *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335436B2 (en) 2009-01-03 2019-07-02 Ray C. Wasielewski Medical treatment composition comprising mammalian dental pulp stem cells
US20100209878A1 (en) * 2009-01-03 2010-08-19 Wasielewski Ray C Enhanced medical implant
US20100209387A1 (en) * 2009-01-03 2010-08-19 Wasielewski Ray C Enhanced medical implant
US20100215617A1 (en) * 2009-01-03 2010-08-26 Wasielewski Ray C Enhanced medical implant
US8470309B2 (en) 2009-01-03 2013-06-25 Ray C. Wasielewski Enhanced medical implant comprising disrupted tooth pulp and tooth particles
US8470308B2 (en) 2009-01-03 2013-06-25 Ray C. Wasielewski Enhanced medical implant comprising disrupted tooth pulp and tooth particles
US8540978B2 (en) 2009-01-03 2013-09-24 Ray C. Wasielewski Treatment composition comprising physically disrupted tooth pulp and non-cultured stem cells in a matrix
US8562969B2 (en) 2009-01-03 2013-10-22 Ray C. Wasielewski Treatment composition comprising physically disrupted tooth pulp and non-cultured stem cells
US20100172863A1 (en) * 2009-01-03 2010-07-08 Wasielewski Ray C Enhanced medical implant
US10328103B2 (en) 2009-01-03 2019-06-25 Ray C. Wasielewski Medical treatment composition comprising mammalian dental pulp stem cells
US20160024460A1 (en) * 2013-03-12 2016-01-28 Agency For Science, Technology And Research Method for culturing cells
US10507266B2 (en) 2013-08-01 2019-12-17 Two Cells Co., Ltd. Cartilage-damage treatment agent and method for producing same
EP2899266A1 (de) * 2014-01-24 2015-07-29 Fresenius Medical Care Deutschland GmbH Verbesserte Differenzierung mesenchymaler Stammzellen zu Osteoblasten
CN112175899A (zh) * 2019-07-04 2021-01-05 陕西佰傲干细胞再生医学有限公司 间充质干细胞成骨定向分化诱导液及其应用
US20220049224A1 (en) * 2019-10-30 2022-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Culture modifications of stem cells to enhance therapeutic recovery from tissue damage and ischemia-reperfusion injury and delayed organ function
CN112608891A (zh) * 2020-12-18 2021-04-06 云南中科灵长类生物医学重点实验室 一种间充质干细胞无血清培养基及其应用
CN114517178A (zh) * 2022-02-25 2022-05-20 北京三有利康细胞科技有限公司 Trolox在延缓间充质干细胞衰老中的应用
CN116590225A (zh) * 2023-05-12 2023-08-15 浙江大学 磷脂酰胆碱在制备促进猪FAPs细胞分化聚酯制剂中的应用

Also Published As

Publication number Publication date
EP2351831B1 (de) 2017-06-14
JP5660572B2 (ja) 2015-01-28
EP2351831A1 (de) 2011-08-03
KR101712501B1 (ko) 2017-03-07
US20160032247A1 (en) 2016-02-04
AU2009315204A1 (en) 2010-05-20
US10131877B2 (en) 2018-11-20
JPWO2010055616A1 (ja) 2012-04-12
AU2009315204A8 (en) 2013-03-28
AU2009315204B2 (en) 2015-03-26
WO2010055616A1 (ja) 2010-05-20
EP2351831A4 (de) 2012-04-18
KR20110084281A (ko) 2011-07-21

Similar Documents

Publication Publication Date Title
US10131877B2 (en) Differentiation-inducing culture medium additive and use thereof
JP4385076B2 (ja) 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用
US10472605B2 (en) Serum-free medium
JP5170443B2 (ja) 骨髄幹細胞（ｂｍｓｃ）を骨分化させる方法およびその使用
JP6191694B2 (ja) 軟骨損傷治療剤及びその製造方法
CA2558520A1 (en) Serum-free suspension culture system for mesenchymal progenitor cells
KR20230135570A (ko) 전구세포 분화용 무혈청 배지
AU2018310000B2 (en) Composition for cryopreservation, method for producing cryopreserved material, cell preparation, method for producing cell preparation, and kit for cryopreservation
WO2024063020A1 (ja) 椎間板治療剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: HIROSHIMA UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KATO, YUKIO;SHAO, JIN CHANG;TSUJI, KOICHIRO;SIGNING DATES FROM 20110407 TO 20110420;REEL/FRAME:026231/0448

Owner name: TWO CELLS CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KATO, YUKIO;SHAO, JIN CHANG;TSUJI, KOICHIRO;SIGNING DATES FROM 20110407 TO 20110420;REEL/FRAME:026231/0448

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION